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Myoglobin and mitochondria have been studied extensively over the past century; however, the 
mechanisms by which they interact still remain unclear. Myoglobin is known for its localization 
in skeletal muscle where it stores and transports oxygen to respiring mitochondria. Myoglobin is 
now gaining recognition for its expression in cancer and its function as a nitrite reductase, able to 
reduce nitrite to nitric oxide (NO).  The overall objective of this study is to characterize the 
regulation of mitochondria by myoglobin, specifically in ischemia/reperfusion injury and breast 
cancer. 
Mitochondrial damage is a central component to ischemia/reperfusion injury. Nitrite is 
known to mediate protection after ischemia/reperfusion through its reduction to NO, which S-
nitrosates complex I of the electron transport chain. This S-nitrosation reduces reactive oxygen 
species generation, thereby reducing cell death. Using myoglobin positive and negative cells, this 
study shows that nitrite is only able to mediate protection in myoglobin-expressing cells through 
S-nitrosation. Furthermore, by knocking down complex I by siRNA transfection, it is confirmed 
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 v 
that this protection occurs through complex I. Therefore, myoglobin expression is required for 
nitrite to have protective effects in reperfusion injury.  
Myoglobin has only recently been discovered in cancer tumors; therefore, little is known 
about its function in these tissues. Interestingly, myoglobin expression in breast cancer has been 
associated with better patient prognosis. In this study, stable transfection of myoglobin in MDA-
MB-231 breast cancer cells caused a significant decrease in cell proliferation and marked 
mitochondrial fusion. This fusion of mitochondria resulted in cell cycle arrest at the G1/S phase 
transition of the cell cycle. Further investigation showed that myoglobin expression prevents 
ubiquitination of mitochondrial fusion proteins. Myoglobin-expressing cells therefore have 
extensive mitochondrial fusion, which causes cell cycle arrest and reduced cell proliferation and 
tumor growth in vivo.  
This project has identified that myoglobin is necessary for nitrite to have protective 
effects in ischemia/reperfusion and begun to elucidate the mechanism by which myoglobin is 
beneficial in breast cancer. With further research, myoglobin may be used as a therapeutic target 
for cancer as well as ischemia/reperfusion in other tissues.  
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1.0  INTRODUCTION 
The small oxygen-binding heme protein myoglobin has long been recognized to regulate 
mitochondria in skeletal and cardiac muscle cells through oxygen delivery. Myoglobin is now 
recognized for its expression in tissues beyond skeletal muscle cells including smooth muscle 
and some cancer tumors. Additionally, myoglobin can react with reactive nitrogen species to 
modulate mitochondrial function independent of oxygen delivery. This thesis will investigate 
how these novel functions of myoglobin and how they contribute to regulation of mitochondria 
in two pathological models.  
1.1 MITOCHONDRIA 
Mitochondria were first discovered by Altmann in 1886, with their structure first recognized in 
1857, and were initially thought to be parasites within the cell. Nearly 100 years after their initial 
discovery, Peter Mitchell first described the chemiosmotic theory in 1961 [1]. Together with the 
findings of Warburg and Keilin, this discovery describes how electrons from NADH and FADH2 
enter complexes I and II of the respiratory chain embedded within the inner mitochondrial 
membrane. These electrons are then transferred to complex III through ubiquinone and finally by 
cytochrome c to complex IV (cytochrome c oxidase) where oxygen is reduced to water. 
Simultaneously, protons are pumped from the matrix of the mitochondria into the inter-
 2 
membrane space, creating an electrochemical gradient (Δμ) and a buildup of protons in the 
intermembrane space. This gradient drives the re-entry of protons into the mitochondrial matrix 
via complex V (ATP synthase). As protons move back into the matrix, ADP and inorganic 
phosphate combine, generating ATP. Mitochondria are known for their role in energy 
production, as they are typically referred to as “powerhouses of the cell”, generating the 
necessary amount of ATP to sustain the metabolic functions of the cell (Figure 1) [2, 3]. 
In addition to energy production, mitochondria are now recognized to play an important 
role in maintaining cellular homeostasis through generation of reactive oxygen species (ROS) 
and initiation of the apoptotic cascade. While the majority of electrons pass through complexes I 
through IV of the electron transport chain, approximately 2% of electrons leak out prematurely, 
which typically occurs at complexes I and III. These electrons can then oxidize oxygen, forming 
superoxide (O2
-), which is rapidly converted to hydrogen peroxide (H2O2) by manganese 
superoxide dismutase (MnSOD) in the mitochondrial matrix and copper/zinc superoxide 
dismutase (Cu/Zn SOD) in the cytosol [4].  
 
Figure 1. Mitochondria produce ATP and generate ROS.   
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ROS were once thought to only be associated with tissue damage and pathological 
conditions. However, low levels of ROS are now recognized to be important in a variety of 
cellular signaling processes including cell growth and proliferation as well as the inflammatory 
response. Additionally, ROS play a significant role in protection in the heart from 
ischemia/reperfusion injury, which will be addressed in Aim 1 [5]. It should be noted, however, 
that high levels of ROS cause protein and lipid oxidation and DNA damage, resulting in cell 
death and tissue damage [6]. 
Another important function of mitochondria is the initiation of the apoptotic cascade. 
Cytochome c is released from cardiolipin in the inner mitochondrial membrane into the cytosol, 
where it binds apoptotic protease activating factor-1 (APAF-1), forming an apoptosome. The 
apoptosome then binds and cleave procaspase 9, resulting in its fully activated form, which 
subsequently stimulates the caspase cascade and commits the cell to apoptosis [7]. 
1.1.1 Mitochondria are dynamic structures  
In order to maintain the energy demands of the cell, mitochondria constantly come together 
(fusion) and break apart (fission). These fission and fusion events are mediated by guanosine 
triphosphotases (GTPases) of the dynamin protein family. Specifically, fission is mediated by 
dynamin related protein-1 (drp1) while fusion is mediated by the mitofusins (mfn) 1 and 2 [8]. 
Mitochondrial fission typically occurs in stressed cells and it has been shown to occur 
almost simultaneously with release of cytochrome c from the inner mitochondrial membrane. 
Moreover, fission occurs to segregate damaged mitochondria from fully functioning 
mitochondria, allowing damaged mitochondria to be targeted for autophagy. Additionally, 
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fission is crucial in actively growing and diving cells to provide each daughter cell with 
appropriate number of mitochondria [8].  
As shown in Figure 2, fission occurs when drp1 is recruited from the cytosol to the 
mitochondria, forming spiral-like structures around the membrane. These proteins constrict the 
mitochondria, severing both inner and outer membranes and forming two separate mitochondria 
[8]. 
 
Figure 2. Mitochondrial fission is mediated by drp1 [9]. 
 
Mitochondrial fusion most commonly occurs to maximize respiratory capacity. It has 
been shown that mitochondria become increasingly fused when cells are forced to undergo 
oxidative phosphorylation by withdrawing glucose as a source for glycolysis [10]. The mitofusin 
proteins, mfn 1 and 2 are responsible for mediating fusion and are localized to the outer 
mitochondrial membrane. As shown in Figure 3, these proteins direct mitochondrial fusion by 
forming homo- and hetero-oligomeric complexes, tethering two membranes together, forming a 
single mitochondrion [8, 10].  
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Figure 3. Mitochondrial fusion is mediated by mfn1 and mfn2 [9]. 
1.2 MYOGLOBIN  
The small protein myoglobin is one of the most well characterized proteins to date. Myoglobin 
was first discovered as a muscle pigment, referred to as muscle hemoglobin, by Mörner in 1879 
[11]. Mörner distinguished myoglobin from hemoglobin by their different absorbance spectra 
and suggested the name monochrome for this protein. In 1921, the term myoglobin was coined 
by Günther who confirmed Mörner’s results [12, 13]. In 1958, John Kendrew was the first to 
resolve the three-dimensional structure of myoglobin by X-ray crystallography, making 
myoglobin the first protein to be described at the atomic level. In 1962, John Kendrew shared the 
Nobel Prize in chemistry with Max Perutz for this discovery [14]. 
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1.2.1 Myoglobin structure and localization 
Myoglobin is a 17 kD monomeric heme protein consisting of a single polypeptide chain of 153 
amino acids [15]. It is a member of the globin superfamily, meaning it contains a globin fold 
comprising a series of eight alpha helices [3, 16]. These alpha helices are folded around a 
hydrophobic core that contains the heme prosthetic group, which consists of a porphyrin ring 
bonded to a central iron atom by four nitrogen atoms and the proximal histidine residue at the 
fifth coordination site (His 93), as shown in Figure 4 [3, 17]. The outside surface of the 
myoglobin protein is composed primarily of hydrophilic residues, allowing the molecules to 
easily move past one another in a concentrated solution [18]. Oxygen, as well as small ligands 
such as carbon monoxide (CO) and nitric oxide (NO), bind myoglobin at the sixth coordinate site 
of the heme iron. The distal histidine (His 64) becomes important in the binding of these small 
molecules, as it facilitates binding through hydrogen bonding [19].  
 
 
Figure 4. Myoglobin is an oxygen-binding heme protein [17]. 
 
 7 
Myoglobin is known for its expression in cardiac and skeletal muscle of all large 
vertebrates, with a relatively preserved amino acid sequence and three-dimensional structure. 
The myoglobin content in cardiac and skeletal muscle is closely correlated with cytochrome c 
oxidase expression, capillary density, and increases dramatically with exercise. The basal 
myoglobin concentration in cardiac muscle is approximately 200-300 μmol kg-1 wet weight while 
the concentration in skeletal muscle is much higher at 400-500 μmol kg-1 wet weight [16, 18]. 
Interestingly, myoglobin has recently been discovered in low concentrations in smooth muscle 
cells [20, 21] as well as tumor tissue of non-muscle origin [22-24]. Early investigation of 
myoglobin expression in cancer revealed myoglobin improves patient outcomes [22]. However, 
the role of myoglobin expression in these tissues has not been elucidated. The effect of 
myoglobin expression on mitochondria in cancer cells will be investigated in Aim 2.  
1.3 REGULATION OF MITOCHONDRIA BY MYOGLOBIN  
1.3.1 Myoglobin is an oxygen storage protein   
Myoglobin’s role in oxygen storage was discovered fairly early and remains its most well-known 
and accepted function. Myoglobin has a very high affinity for oxygen, with a P50 of 3.1μM [3, 
25]. In tissues requiring significant energy production such as cardiac muscle, myoglobin is 
present in very high concentrations, allowing for sustained muscle contraction. Studies have 
shown that at the onset of contraction, a new deoxygenated steady-state is reached within 20-40 
seconds, suggesting that myoglobin releases oxygen to respiring mitochondria, driving muscle 
contraction [16, 26].  
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1.3.2 Myoglobin-facilitated oxygen diffusion   
Another, somewhat controversial function of myoglobin is its ability to bind and transport 
oxygen within the cell to hypoxic respiring mitochondria. This function of myoglobin was first 
reported by Wittenberg in which he described how oxygen diffusion is enhanced from the 
sarcolemma to the mitochondrion due to myoglobin’s ability to quickly bind oxygen, diffuse 
through the cell, and unload oxygen to respiring mitochondria [27-29].  
In 1996, Johnson et al. showed that oxygen diffuses faster in myoglobin-containing 
solutions than in non-myoglobin solutions [29, 30]. Due to its high affinity for oxygen, 
myoglobin is able to quickly bind oxygen as it diffuses from the capillary into the cell, transport 
it to mitochondria, and finally release oxygen as oxygenated myoglobin comes to equilibrium 
with deoxygenated myoglobin. In 2000, Takahashi et al. demonstrated in isolated 
cardiomyocytes that significant intracellular gradients are developed when stimulating 
mitochondrial respiration. These gradients extend from the core of the cell, which is anoxic, to 
the plasma membrane. Moreover, upon inactivation of cytosolic myoglobin with 5 nM NaNO2 
treatment, the anoxic core region expands significantly. These results suggest myoglobin binds 
oxygen at the plasma membrane and carries it deeper within the cell where it unloads oxygen to 
respiring mitochondria. Thus, by carrying oxygen away from the plasma membrane, myoglobin 
effectively extends the oxygen gradient within the cell [31].  
In 2001, with the generation of myoglobin-deficient mice (Mb-/-), Merx et al. showed 
that oxygen consumption in cardiomyocytes from Mb-/- mice is lower than oxygen consumption 
from wild type (WT) cardiomyocytes when ambient PO2 is decreased from 40mmHg to 8mmHg. 
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Therefore, in WT cardiomyocytes myoglobin releases bound oxygen to respiring mitochondria, 
allowing for continued oxygen consumption as ambient PO2 decreases. In Mb-/- cardiomyocytes, 
however, myoglobin is not present to release its stored oxygen to mitochondria, resulting in 
decreased oxygen consumption [32].  
1.3.3 Myoglobin reacts with reactive nitrogen species to modulate mitochondrial function 
Nitrite is present in concentrations of 100-250 nM in the plasma and 1-10 μM in tissue and is 
now recognized as a bioavailable storage pool for the signaling molecule nitric oxide (NO). 
Nitrite can be reduced to nitric oxide through several mechanisms including acidic 
disproportionation, enzymatic conversion by xanthine-oxidoreductase, and mitochondrial 
enzymes. It is well known that deoxyhemoglobin has nitrite reductase activity, able to react with 
bioavailable nitrite in the blood, generating nitric oxide, which subsequently causes vasodilation 
[33, 34]. In 2007 it was shown that in low oxygen concentrations, deoxymyoglobin also has 
nitrite reductase activity, which occurs by the reaction below, converting ferrous (Fe2+) 
myoglobin to metmyoglobin (Fe3+) and generating nitric oxide. Notably, the reduction of nitrite 
by deoxymyoglobin occurs approximately 36 times faster than deoxyhemoglobin due to its low 
heme redox potential [35]. 
 
𝑑𝑒𝑜𝑥𝑦𝑀𝑏(𝐹𝑒2+) + 𝑁𝑂2
− + 𝐻+
 
→  𝑚𝑒𝑡𝑀𝑏(𝐹𝑒3+) + 𝑁𝑂 
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Nitric oxide also reacts with myoglobin, however this occurs under normal oxygen 
tensions when myoglobin is oxygenated. The ability of nitric oxide to react with heme centers is 
now recognized as one of its most important characteristics. As shown in the reaction below, 
nitric oxide reacts with oxygenated myoglobin converting ferrous (Fe2+) myoglobin to 
metmyoglobin (Fe3+) and generating nitrate [36, 37].  
 
𝑀𝑏(𝐹𝑒2+)𝑂2 + 𝑁𝑂
 
→ 𝑚𝑒𝑡𝑀𝑏(𝐹𝑒3+) + 𝑁𝑂3
− 
1.3.4 Nitric oxide regulates mitochondria 
It the late 1990’s, nitric oxide was found to modulate mitochondrial function through inhibition 
of cytochrome c oxidase (complex IV) in low oxygen conditions. It has now been shown that 
bioavailable nitrite reacts with deoxymyoglobin, producing nitric oxide, which reversibly binds 
cytochrome c oxidase at the binuclear center (CuB/cytochrome a3) active site, inhibiting 
respiration. Because nitric oxide must compete with oxygen for binding to cytochrome c oxidase, 
this inhibition is especially pronounced at low oxygen tensions [38]. 
In 2001, Brunori proposed that the reaction of myoglobin and nitric oxide in normoxia is 
important to avoid inhibition of cytochrome c oxidase by nitric oxide. This becomes extremely 
important in cardiac muscle, which is under continuous energy demand due to constant 
contraction. Therefore, mitochondria have to continually respire to generate the necessary 
amount of ATP to sustain this contraction. Thus, in normoxia, myoglobin scavenges nitric oxide, 
allowing respiration to continue uninhibited [36]. Myoglobin’s ability to generate nitric oxide is 
also very important. When oxygen is limited, inhibition of respiration by nitric oxide serves as a 
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mechanism to conserve the little oxygen present in the tissue and extend oxygen gradients deeper 
within the tissue [39]. Therefore, under normoxic conditions, myoglobin will scavenge nitric 
oxide, thereby allowing respiration to continue and in hypoxia myoglobin will generate nitric 
oxide in an attempt to preserve oxygen and extend oxygen gradients within the cell [41]. These 
novel reactions of myoglobin become particularly important in the context of 
ischemia/reperfusion injury, which will be the focus of Aim 1.  
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2.0  RESEARCH OBJECTIVES 
While myoglobin and mitochondria have been studied extensively in the context of oxygen 
delivery and utilization, it has only recently been recognized that they interact by mechanisms 
not involving oxygen delivery. As described in the previous section, myoglobin has many 
functions besides oxygen storage and delivery and is expressed in more tissues than just skeletal 
muscle. Thus, the focus of this thesis is to elucidate the mechanisms by which myoglobin 
regulates mitochondrial function beyond oxygen storage and delivery.  
 
Aims and Hypotheses 
Specific Aim 1: Determine whether myoglobin mediates nitrite dependent protection in 
ischemia/reperfusion. 
Hypothesis: Myoglobin catalyzes the reduction of nitrite to nitric oxide to mediate complex I  
 S-nitrosation in ischemia/reperfusion. 
   
Specific Aim 2: Investigate the effect of myoglobin expression on mitochondrial dynamics 
and cell proliferation in breast cancer 
Hypothesis: Myoglobin-dependent changes in mitochondrial dynamics and function modulates 
cell survival and proliferation in normoxic breast cancer cells.  
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3.0  EXPERIMENTAL METHODS 
3.1 REAGENTS 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless noted. MDA-
MB-231 cells were purchased from ATCC (Rockville, MD, USA).  
3.2 STABLE TRANSFECTION OF MYOGLOBIN IN MDA-MB-231 CELLS 
GFP-tagged human myoglobin (GFP-Mb) was purchased from Origene (RG212352, Rockville, 
MD, USA). Bacterial transformation was performed using several different DNA concentrations. 
DNA was added to 100μl MDA-MB-231 cells (231) and incubated at 42°C for 45 seconds 
followed by incubation on ice for 2 minutes. 900μl S.O.C medium was added to tubes and 
allowed to shake at 225 RMP at 37°C for 1 hour. 200μl of this mixture was spread on agar plates 
containing 100μg/μl ampicillin and incubated overnight at 37°C. Viable colonies were chosen 
and glycerol stocks prepared. DNA was then purified using a Qiagen plasmid kit (Venlo, 
Netherlands).  
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231 cells were transfected with GFP-Mb DNA using Lipofectamine 2000 (Life 
Technologies, Grand Island, NY, USA). Approximately 48 hours after transfection, cells were 
passaged in media containing geneticin (Life Technologies) to select only for cells resistant to 
the antibiotic. Single cells from resistant colonies were transferred to 96-well plates to confirm 
they were able to yield antibiotic-resistant colonies, which were then expanded.   
3.3 MYOGLOBIN-EXPRESSING CHO CELLS 
CHO cells stably transfected to express human myoglobin were generated by Dr. Dara Frank and 
given as a gift from Dr. Neil Hogg from the Medical College of Wisconsin.  
3.4 CELL CULTURE 
231 and myoglobin-expressing 231 cells (231Mb) were cultured in Dulbecco's Modified Eagle 
Medium (Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) 
(Life Technologies), 1% penicillin-streptomycin (Lonza, Basel, Switzerland), and 1% Geneticin 
(DMEM growth medium). Chinese hamster ovary (CHO) cells and myoglobin-expressing CHO 
cells (CHOMb) were cultured in Ham’s F12 Nutrient Mixture (Invitrogen) supplemented with 
10% FBS, 1% penicillin-streptomycin, 1% Geneticin, and 0.001% Hemin. Cells were stored in 
an incubator maintained at 37°C, 21% O2, and 5% CO2. 
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3.5 BRIGHT FIELD IMAGING 
Bright field images were taken with a Zeiss Axiovert 40 CFL microscope (Carl Zeiss 
Microscopy, Thornwood, NY, USA) and analyzed with AxioVision software Rel. 4.8 (Carl Zeiss 
Microscopy). 
3.6 S-NITROSATION DETECTION 
S-nitrosation was detected by tri-iodide based reductive chemiluminescence in the presence and 
absence of acidified sulfanilamide as previously described [42].  Briefly, after treatment of cells 
with nitrite (in the presence and absence of myoglobin), SNO was stabilized with 100 mM 
Diethylenetriaminopentaacetic acid (DTPA), 4 mM Cyanide/ferricyanide (III), 10 mM N-
Ethylmaleimide, and 1% NP-40.  The sample was then divided into three parts: one left 
untreated, one  treated with 10% acidified sulfanilamide (v/v) to eliminate nitrite, and 
one  treated with 5mM mercuric chloride and 10% acidified sulfanilamide to eliminate SNO and 
nitrite.  The fractions were then injected into a triiodide-containing vessel that was connected to 
an NO chemiluminescence detector (Sievers).  
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3.7 CHO NDUFAF1 TRANSFECTION 
CHOR and CHOMb cells were allowed to grow to approximately 70% confluence. Cells were 
washed once with 1X PBS and media replaced with Opti-MEM® reduced serum medium 
(Invitrogen) Cells were transfected with either control (sc-37007, Santa Cruz Biotechnology, 
Santa Cruz, CA) or NDUFAF1 (SI01602251, Qiagen, Hilden, German) targeted siRNA using 
Lipofectamine 2000 transfection reagent (Invitrogen).  
3.8 ISCHEMIA/REPERFUSION SIMULATION 
Ischemia was simulated by incubating cells in hypoxia (1% O2, 5% CO2) for two hours in 
modified Esumi Buffer (137 mmol/L NaCl, 12 mmol/L KCl, 0.5 mmol/L MgCl2, 0.9 mmol/L 
CaCl2, 20 mmol/L HEPES; 20 mmol/L 2-deoxy-D-glucose (2-DG), pH 6.2). Reperfusion was 
simulated by reoxygenating cells in 20% O2 (5% CO2) in the same modified Esumi Buffer for 
one hour. Nitrite-treated cells were reoxygenated in 20% O2 (5% CO2) in modified Esumi Buffer 
supplemented with 5μM NO2- for one hour.  
3.9 LACTATE DEHYDROGENASE ACTIVITY ASSAY 
Lactate dehydrogenase (LDH) activity in the media was determined by kinetically measuring the 
rate of NADH oxidation to NAD+ using a Synergy plate reader (BioTek Instrument Inc. 
Winooski, VT) at 340nm.  
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3.10 WESTERN BLOT 
Samples were lysed in buffer containing 20 mM Tris/HCl pH 7.5, 1 mM EDTA, 150 mM NaCl, 
1% NP40, 1% sodium deoxycholate, 1X Phenylmethylsulfonyl fluoride (PMSF) and 1X protease 
inhibitors. Tissue samples were briefly homogenized prior to lysis. Protein concentrations were 
determined by a BCA assay (Pierce, Rockford, IL, USA). Cell lysates were prepared and 
denatured at 95°C. Equal amounts of protein were loaded in gels ranging in percentages from 7-
15 and proteins separated by SDS-PAGE. Proteins were then transferred to a nitrocellulose (Bio-
Rad Laboratories, Hercules, CA, USA) or polyvinylidene difluoride (PVDF) membrane (Bio-
Rad Laboratories). After transfer, membranes were incubated in LI-COR® Blocking Buffer (LI-
COR Biosciences, Lincoln, NE, USA) diluted 1:1 in PBS at room temperature for one hour to 
reduce nonspecific antibody binding. Membranes were incubated with primary antibodies diluted 
1:500 in a 5% BSA PBS solution for 2 hours at room temperature or overnight at 4°C. 
Antibodies used include NDUFAF1 (sc-86755, Santa Cruz Biotechnology), mfn1 (sc-50330, 
Santa Cruz Biotechnology), drp1 (sc-32898, Santa Cruz Biotechnologies), parkin (#2132, Cell 
Signaling Technology, Danvers, MA, USA), p21 (BD Pharmingen, San Jose, CA, USA), cyclin 
E (sc-481, Santa Cruz Biotechnology), or biotin (B7653, Sigma). After incubation with primary 
antibody, blots were washed 5 times for 5 minutes in 0.01% TBST and incubated with 
appropriate fluorophore conjugated secondary antibodies diluted 1:10,000 in a 5% BSA PBS 
solution for one hour at room temperature. Membranes were then washed for 5 times for 5 
minutes in TBST and imaged with a LI-COR® odyssey imaging system (LI-COR®, Lincoln NE, 
USA).  
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Images were analyzed using LI-COR® odyssey infrared imaging software version 3.0 
(LI-COR®). To normalize protein concentration to total protein, blots were stripped with LI-
COR® stripping buffer (LI-COR® Biosciences), washed, and reprobed with antibodies against 
either α-Tubulin (CP06, Calbiochem, Billerica, MA, USA) or β-actin (A5316, Sigma). 
3.11 3H THYMIDINE INCORPORATION 
Cells were plated in a 24-well plate and incubated with media containing 3H Thymidine 
(5Ci/mL) for 24 hours. To determine amount of 3H thymidine incorporation, cells were washed 
with 1mL 1X PBS and incubated in 5% TCA at 4°C for 30 minutes. Cells were then washed 
once with 5% TCA and 1X PBS and incubated in 0.2N NaOH at room temperature for 30 
minutes to precipitate DNA.  Each sample was then added to a scintillation tube containing 4mL 
scintillation fluid (Perkin Elmer, Waltham, MA, USA) and read in a scintillation counter.  
3.12 CRYSTAL VIOLET STAINING 
Media was aspirated from 24-well cell plates, 0.25% crystal violet was added to cover the 
bottom of the plate (~100μl), and put on a shaker for 30 minutes. Crystal violet was then washed 
off by dunking the plate in cold water two times and the plate was allowed to dry overnight. 
Crystal violet was dissolved by adding 1% SDS (~200μl) to the plate. Absorbance was measured 
in a Synergy plate reader (BioTek Instrument Inc.), which is correlated to DNA content.  
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3.13 SCRATCH ASSAY 
Cells were plated in 6-well plates and allowed to grow approximately to 70% confluence. Plates 
were scratched and imaged for a 0 hour time-point. Cells were incubated at 37°C (20% O2, 5% 
CO2) for 24 hours. Cells were then imaged at the 24-hour time point. Area of the scratch was 
quantified with NIH ImageJ software and percent closure calculated using the equation below. 
𝑝𝑒𝑟𝑐𝑒𝑛𝑡 𝑐𝑙𝑜𝑠𝑢𝑟𝑒 =  
𝐴𝑡=24 − 𝐴𝑡=0
𝐴𝑡=0
×  100 
3.14 APOPTOSIS MEASUREMENT 
Apoptosis was measured in 231 and 231Mb cells by annexin V staining and flow cytometry 
analysis. Cells were trypsinized, washed with 1X PBS, and resuspended in 10X binding buffer 
(51-66121E, BD Pharmingen) at a concentration of approximately 1×106 cells/mL. Cells were 
then incubated with propidium iodide and annexin V (560506, BD Biosciences, San Jose, CA, 
USA) for 15 minutes in the dark and analyzed by flow cytometry within 1 hour.  
3.15 FLUORESCENCE IMAGING 
Cells plated on coverslips in a 6-well plate were first rinsed with 1X PBS and fixed in 4% PFA 
for 30 minutes on a shaker. Cells were then rinsed in 0.1% Triton X-100 in PBS and incubated 
with Li-Cor® blocking buffer diluted 1:1 in PBS for 1 hour on a shaker. Cells were stained with 
rabbit anti-TOM20 (sc-11415, SantaCruz Biotechnologies) diluted 1:1000 in 50% LiCor® PBS 
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solution overnight at 4°C. Cells were rinsed three times with 1X PBS and stained with goat anti-
rabbit Cy3 secondary antibody (A10520, Invitrogen) for two hours at room temperature. Cells 
were imaged with a confocal microscope using a 60X objective and 3X optical zoom with a step 
size of 0.77μm.  
3.16 TRANSMISSION ELECTRON MICROSCOPY 
Cells were grown to approximately 80% confluency in a 6-well plate. Fist, cells were rinsed once 
with 1X PBS and fixed with 2.5% glutaraldehyde in PBS for 1 hour at room temperature on a 
shaker. After fixation cells were rinsed with 1X PBS 3 times for 10 minutes each. Cells were 
then post-fixed for 1 hour at 4° C in 1% OsO4 with 1% potassium ferricyanide and washed 3 
times in 1X PBS for 10 minutes each. Cell monolayers were dehydrated in a series of alcohol 
(30%, 50%, 70%, and 90%) for 10 minutes each with three washes in 100% ethanol for 15 
minutes each. Cell monolayers were then incubated in epon resin 3 times for 1 hour each and 
samples collected using beam capsules after removal of the final epon incubation. Samples were 
polymerized at 37°C overnight then 60°C for 48 hours. Samples were then removed from the 
dish and sectioned with an ultramicrotome using a diamond knife. Samples were imaged at 
25,000X using a JEOL JEM 1011 transmission electron microscope (JEOL Ltd., Tokyo, Japan).  
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3.17 HYDROGEN PEROXIDE MEASUREMENT 
Cytosolic hydrogen peroxide (H2O2) levels were quantified using Amplex® Red (Life 
Technologies) per manufacturer’s instructions. Cells were collected by trypsinizing and 
resuspending in STE buffer. Cells were then added to a 96-well plate and with the Amplex Red 
master mix (PBS, HRP, Amplex Red reagent) and the mitochondrial-targeted ROS scavenger 
mitoTEMPOL or STE for control groups. Fluorescence (570/585 nm) was read using a Synergy 
plate reader (BioTek Instrument Inc.). Data was analyzed and normalized to protein 
concentration determined by Pierce BCA assay (Thermo Fisher Scientific, Rockford, IL, USA).  
3.18 SUPEROXIDE MEASUREMENT 
Mitochondrial superoxide was measured using MitoSOX™ Red reagent (Life Technologies) per 
manufacturer’s instructions. Cells were collected by trypsinizing and resuspending in HBSS 
buffer. Cells were then added to a 96-well plate and MitoSOX™ Red master mix (MitoSOX ™ 
Red and HBSS). Fluorescence (510/580 nm) was read immediately using a Synergy plate reader 
(BioTek Instrument Inc.). Data was analyzed and normalized to protein concentration 
determined by Pierce BCA assay.  
 22 
3.19 MDA-MB-231 SIRNA TRANSFECTION 
231 and 231Mb cells were plated and allowed to grow to approximately 70% confluence. Cells 
were washed one time with PBS and media was changed to Opti-MEM® reduced serum medium 
(Life Technologies). Cells were transfected with human myoglobin (sc-35995, Santa Cruz 
Biotechnology), mfn1 (sc-43927, Santa Cruz Biotechnology), or mfn2 (sc-43928, Santa Cruz 
Biotechnology) targeted siRNA using Santa Cruz siRNA Transfection Reagent (sc-29528, Santa 
Cruz Biotechnology) according to the manufacturer’s instructions.  
3.20 MFN1 IMMUNOPRECIPITATION 
Cell lysates were collected and protein concentration determined by BCA assay. Lysates of equal 
protein concentration were incubated with 1-2μg mfn1 antibody (sc-50330, Santa Cruz 
Biotechnologies) at 4°C on a tumbler overnight. The next day, samples were incubated with 
protein A/G beads (sc-2003, Santa Cruz Biotechnology) for 1-3 hours at 4°C on a tumbler. 
Samples were then boiled at 95°C, beads removed by centrifugation, and separated by SDS-
PAGE. Ubiquitination was detected using an ubiquitin antibody (sc-9133, Santa Cruz 
Biotechnology).  
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3.21 MEASUREMENT OF PARKIN OXIDATION BY BIOTIN SWITCH 
231 and 231Mb cells were collected and reacted on ice in lysis buffer (1% SDS, 0.5% Triton-
X100, 0.1mM Neocuprion in PBS) for 30 minutes. Cell lysates of equal protein concentration 
were treated with 20mM N-ethylmaleimide (NEM) to block free thiols. 10mM Tris (2-
carboxyethyl) phosphine (TCEP) was used to reduce disulfide bonds and NEM-PEG2-biotin to 
label these reduced free thiols. As positive controls, lysates and bovine serum albumin were not 
treated with NEM at the block step, but reacted with TCEP at the label step, which allows all 
cysteine residues to be tagged with biotin. Negative controls have few free thiols available to be 
biotin-labeled, as they are not treated with TCEP at either the blocking or label step. 
Streptavidin beads were used to pull down biotinylated proteins in the albumin positive 
control and parkin was pulled down in the 231 and 231Mb samples using a standard 
immunoprecipitation procedure described previously. Samples were boiled at 95°C for 5 
minutes, beads removed by centrifugation, and separated by SDS-PAGE. A biotin antibody was 
used to detect only biotinylated proteins.  
3.22 ANIMALS 
Ten 4-5 week old female NOD.CB17-Prkdcscid/J mice were purchased from Jackson 
Laboratories (Bar Harbor, ME). Following a 3-day acclimation period, mice were placed on 
irradiated AIN-76A diet (Harlan-Teklad, Indianapolis, IN).  Mice were fed this diet for the 
remainder of the study.  After 1 week on diet, the mice were orthotopically injected in both 
inguinal mammary fat pads with 3 x 106 control 231 or 231Mb cells.  Cells were cultured to 
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approximately 40-60% confluency in culture dishes.  Dishes were washed with PBS, trypsinized, 
centrifuged at 1100 RPM for 5 minutes, and diluted to 108 cells/mL serum-free media.  Tumor 
growth was measured using Vernier calipers and recorded each week beginning when tumors 
became measurable.  Tumor volume was by using the following equation:  
𝑡𝑢𝑚𝑜𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝑚3) =
𝑙𝑒𝑛𝑔𝑡ℎ × 𝑤𝑖𝑑𝑡ℎ2
2
 
The study was terminated when the average tumor volume in the control group 
approached 1.5 cm3.  At the time of sacrifice, the mice were euthanized by CO2 overdose.  
Tumors were harvested from each animal and weights were recorded.  
3.23 STATISTICS 
All values are expresses at mean ± SEM. Single comparisons were tested for significance by a 
two-tailed Student’s t-test. ANOVA was used when comparing multiple groups with a 
Bonferroni post-hoc analysis to correct for multiple comparisons. Differences were considered 
significant when p<0.05.   
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4.0  RESULTS 
4.1 AIM 1 
Nitrite, an anion ubiquitously expressed in biology, has been shown to be protective against 
ischemia/reperfusion injury. We can get nitrite from a variety of sources in the diet including 
leafy green vegetable and cured meat as well as from the oxidation of nitric oxide. It is present in 
physiology at approximately 100-250 nM in the plasma and 1-10 μM in tissue.  
In 2007, Shiva et al. showed that nitrite is protective against ischemia/reperfusion injury 
in the heart. Cardiac ischemia/reperfusion injury was simulated in a murine model by ligating the 
left coronary artery for 30 minutes followed by 24 hours of reperfusion. As shown in Figure 5, 
nitrite (48 nmol) was supplemented either 24 hours prior to reperfusion (PC) or immediately 
before the reperfusion period (acute) [42]. 
 
Figure 5. Procedure for in vivo ischemia/reperfusion simulation in the heart in a murine model. Ischemia 
was simulated by ligating the left coronary artery for 30 minutes followed by 24 hours of reperfusion. Nitrite was 
given 24 hours prior to reperfusion (PC) or immediately before (acute) [42].  
 26 
 
These results showed that regardless of when nitrite was given, it was protective against 
tissue damage and significantly reduced the infarct size in the heart (Figure 6) [42]. 
 
Figure 6. Nitrite significantly reduces infarct size after ischemia/reperfusion. After 30 minutes of ischemia 
and 24 hours reperfusion, nitrite was able to protect the heart against tissue damage regardless of whether it was 
given 24 hours before the reperfusion period or immediately before [42].  
 
It was further shown by Hendgen-Cotta et al that myoglobin is necessary for nitrite to 
have protective effects by performing the same ischemia/reperfusion simulation in myoglobin 
deficient mice [43]. Surprisingly, myoglobin deficient mice are viable and show no obvious 
physiological phenotype [44]. As shown below in Figure 7, ischemia was simulated by ligating 
the left coronary artery for 30 minutes followed by 24 hours of reperfusion. Nitrite (48 nmol) 
was supplemented 5 minutes prior to the reperfusion period [43].  
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Figure 7. Procedure for in vivo ischemia/reperfusion simulation in the heart in a murine model. Ischemia 
was simulated by ligating the left coronary artery for 30 minutes followed by 24 hours of reperfusion. Nitrite was 
given 5 minutes before reperfusion [43]. 
 
Upon analysis of infarct size in the heart, they found that under control conditions, wild 
type (Mb+/+) and myoglobin deficient (Mb-/-) mice had no significant difference in infarct size. 
However, when nitrite was supplemented, it significantly reduced infarct size in Mb+/+ mice 
whereas it had no protective effects in Mb-/- mice (Figure 8) [43]. 
 
Figure 8. Nitrite significantly reduces infarct size in wild type (Mb+/+) but not myoglobin deficient  
(Mb-/-) mice after ischemia/reperfusion. Under control conditions, there is no significant difference between Mb+/+ 
and Mb-/- mice in infarct size. When nitrite is given, infarct size is significantly reduced in Mb+/+ mice but not  
Mb-/- mice [43].  
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Therefore, myoglobin is necessary for nitrite to mediate protection in 
ischemia/reperfusion. As previously described, myoglobin is a known regulator of mitochondrial 
function and notably, mitochondria are a central component to ischemia/reperfusion injury. 
During ischemia, oxygen is not available to be used as the final electron acceptor at complex IV 
of the electron transport chain, causing electrons to build up within the chain. Cells are then 
forced to generate ATP through glycolysis, which is a less efficient energy production method. 
ATP synthase (complex V) also begins to hydrolyze ATP in an attempt to maintain the 
membrane potential within the mitochondria; resulting in an overall reduction in ATP production 
[43, 46]. 
During reperfusion, when oxygen again becomes available, electrons rapidly re-enter the 
chain causing the electrons that had built up within the chain to leak out, resulting in ROS 
production. These ROS can subsequently oxidize proteins and lipids and cause DNA damage as 
well as cause cytochrome c release, causing in cell death [43, 46]. In 2007, Shiva et al. showed 
that treating isolated mitochondria with 20 μM nitrite significantly reduces ROS production after 
simulated ischemia/reperfusion (Figure 9) [42].  
 
Figure 9. Nitrite treatment significantly reduces ROS production in isolated mitochondria after 
ischemia/reperfusion. Amplex Red measurement of ROS generation over time showed that after ischemia 
reperfusion, significant ROS are generated (blue dots). When treated with 20 μM nitrite (red dots), ROS production 
is reduced almost to that of control levels (green dots) [42]. 
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This study also showed that treated isolated mitochondria with nitrite significantly 
increases mitochondrial protein S-nitrosation after an anoxic period (Figure 10, top). They 
further showed that this S-nitrosation specifically occurs at complex I of the electron transport 
chain (Figure 10, bottom) [42]. This S-nitrosation of complex I is likely responsible for reducing 
ROS production in ischemia/reperfusion.  
  
 
Figure 10. Nitrite treatment significantly increases complex I S-nitrosation. Treating isolated mitochondria 
with 480 nmol nitrite significantly increases mitochondrial protein S-nitrosation (top). Further analysis revealed this 
S-nitrosation occurs at complex I of the electron transport chain (bottom) [42]. 
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More recently in 2013, Chouchani et al. showed that nitrite specifically S-nitrosates the 
ND3 subunit of complex I. As shown in Figure 11, during ischemia, complex I undergoes a 
conformational change, which causes a thiol group on the ND3 subunit to become exposed. 
Nitrite can then S-nitrosate this residue, inactivating complex I, thereby inhibiting electrons from 
entering the chain. This, in turn, inhibits ROS production during reperfusion. Furthermore, this 
post-translational modification is reversible, which allows complex I to be reduced to its original 
active form, thereby permitting respiration to continue as normal after reperfusion [47]. 
 
Figure 11. Nitrite S-nitrosates the ND3 subunit of complex I to inhibit ROS production during reperfusion. 
Nitrite S-nitrosates the ND3 subunit of complex I, resulting in its inactivation, which inhibits ROS production 
during reperfusion. Complex I can then be reduced and return to is active form [47]. 
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As described, it is known that myoglobin as well as S-nitrosation of complex I are 
necessary for mitochondrial protection in ischemia/reperfusion injury. Therefore, the hypothesis 
for this aim is that myoglobin catalyzes the reduction of nitrite to nitric oxide to mediate complex 
I S-nitrosation in ischemia/reperfusion, thereby reducing cell death and tissue damage.   
 
4.1.1 Stable transfection of human myoglobin in CHO cells 
To determine the effect of myoglobin expression on nitrite-mediated protection in 
ischemia/reperfusion, the CHO cell line, which contains no endogenous myoglobin, was used. 
CHO cells were transfected with a vector (CHOR) or human myoglobin (CHOMb). A 
representative western blot in Figure 12 shows CHOR cells do not contain myoglobin and human 
myoglobin was successfully stably transfected in CHOMb cells.  
 
Figure 12. CHO cells were successfully transfected to stably express human myoglobin (CHOMb).   
 
To verify that stable expression of human myoglobin does not cause any significant 
changes in overall morphology of CHO cells, bright field images were taken with a 10X 
objective of both cell lines. These images revealed that myoglobin expression does not cause any 
obvious morphological changes (Figure 13). 
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Figure 13. Stable transfection of myoglobin in CHO cells does not alter overall cell morphology. Bright field 
images show CHOR cells (left) transfected with an empty vector and CHOMb cells (right) transfected to stably 
express human myoglobin.   
 
4.1.2 Nitrite treatment promotes cell survival after ischemia/reperfusion in CHOMb cells  
To simulate ischemia/reperfusion injury in vitro, CHOR and CHOMb cells were subjected to 
hypoxia (1% O2) for 2 hours followed by 2 hours of reoxygenation (20% O2) with 5 μM nitrite 
supplemented before reoxygenation (Figure 14).  At the completion of the reoxygenation period, 
cell death was quantified using the lactate dehydrogenase (LDH) release assay. When cells 
become damaged, LDH, which is responsible for the conversion of lactate to pyruvate, is 
released into the media. As shown in Figure 15, by measuring the rate at which NADH is 
oxidized to NAD+, the amount of LDH can be determined, as they are directly correlated. Results 
are presented as the amount of LDH released into the media as a percent of total LDH, as shown 
in the equation below: 
𝐿𝐷𝐻 (%) =  
𝐿𝐷𝐻𝑚𝑒𝑑𝑖𝑎
𝐿𝐷𝐻𝑚𝑒𝑑𝑖𝑎 + 𝐿𝐷𝐻𝑐𝑒𝑙𝑙
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Figure 14. Procedure for simulating ischemia/reperfusion in vitro. CHOR and CHOMb cells were subjected to 1 
hour of hypoxia (1% O2) followed by 2 hours of reoxygenation (20% O2) with 5 μM nitrite supplemented before 
reoxygenation. Cell death was then quantified by measuring LDH released into the cell media. 
 
 
 
Figure 15. Rationale behind lactate dehydrogenase (LDH) release assay. The rate of NADH oxidized to 
NAD+ is measured, which is directly correlated to the amount of LDH in the media.  
 
As shown in Figure 16, after simulated ischemia/reperfusion with no nitrite treatment, 
CHOR and CHOMb cells experience the same amount of cell death. When 5 μM nitrite was 
supplemented, cell death was significantly reduced in CHOMb but not CHOR cells.  
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Figure 16. Nitrite significantly reduces cell death after ischemia/reperfusion injury in CHOMb cells. After 
ischemia/reperfusion, CHOR and CHOMb cells experience the same level of cell death under control conditions. 
When 5 μM nitrite is supplemented, cell death is significantly reduced in CHOMb but not CHOR cells. Data are 
represented as LDH in the media as a percent of total LDH. Data are represented as mean ± SEM. (# p<0.05). 
 
4.1.3 Treating CHOR and CHOMb cells with nitrite increases protein S-nitrosation in 
CHOMb but not CHOR cells  
To show that myoglobin catalyzes the reduction of nitrite to nitric oxide, which can subsequently 
S-nitrosate proteins within the cell, the level of protein S-nitrosation was measured in the whole 
cell and mitochondria. Shown in Figure 17, treating CHOR and CHOMb cells with nitrite 
significantly increased protein S-nitrosation in both whole cell and the mitochondria in CHOMb 
but not CHOR cells. This suggests myoglobin expression is required to reduce nitrite to nitric 
oxide, which can subsequently S-nitrosate proteins within the cell.  
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Figure 17. Protein S-nitrosation in the whole cell and mitochondria in CHOR and CHOMb cells after nitrite 
treatment. Nitrite treatment increases S-nitrosation levels in the whole cell and mitochondria of CHOMb but not 
CHOR cells. (* p<0.01) 
 
4.1.4 Myoglobin-dependent nitrite-mediated protection occurs through mitochondrial 
complex I  
To determine whether myoglobin and nitrite are mediating protection after ischemia/reperfusion 
through complex I, complex I was knocked down in CHOR and CHOMb cells and subjected to 
ischemia/reperfusion in vitro. Complex I was knocked down by transfecting cells with 
NDUFAF1 (NADH dehydrogenase assembly factor 1) siRNA. NDUFAF1 is a protein required 
for proper complex I assembly; therefore, by silencing NDUFAF1, complex I is effectively 
knocked down. As a control, CHOR and CHOMb cells were also transfected with non-targeted 
siRNA. As shown in Figure 18, after transfections, cells were exposed to the same 
hypoxia/reoxygenation protocol previous described and cell death quantified by LDH release.  
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Figure 18. Procedure for transfecting CHOR an CHOMb cells and simulation of ischemia/reperfusion in vitro. 
CHOR and CHOMb cells were transfected with control or NDUFAF1 siRNA and subjected to 1 hour of hypoxia 
(1% O2) followed by 2 hours of reoxygenation (20% O2) with 5 μM nitrite supplemented before reoxygenation. Cell 
death was then quantified by measuring LDH released into the media.  
 
As shown in Figure 19, when transfected with control siRNA, nitrite significantly reduces 
cell death in CHOMb cells but not CHOR cells, consistent with the results obtained when no 
transfection was performed. When transfected with NDUFAF1 siRNA, nitrite still does not 
provide protection in CHOR cells and the protection previously observed with nitrite treatment 
in CHOMb cells is eliminated. Therefore, myoglobin-dependent nitrite-mediated protection 
occurs through complex I.   
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Figure 19. Silencing complex I eliminates nitrite’s protective effects in CHOMb cells. When transfected 
with control siRNA, nitrite significantly reduces cell death in CHOMb but not CHOR cells. When transfected with 
NDUFAF1 siRNA, the protection previously mediated by nitrite in CHOMb cells is eliminated. Two-way ANOVA 
with Bonferroni correct was used to determine significance. Data are presented as mean ± SEM. (# p<0.05; * 
p<0.01) 
  
As shown in the pathway in Figure 20, the findings presented in this aim show that 
myoglobin catalyzes the reduction of nitrite to nitric oxide, which can subsequently S-nitrosate 
complex I to inhibit ROS production during reperfusion. By reducing ROS production, cell death 
is reduced, thereby promoting cell survival and mitigating tissue damage.  
 
0
50
100
150
L
D
H
 R
e
le
a
s
e
 (
%
)
# *
ns
control
5mM NO2
-
CHOR CHOR CHOR CHOMb CHOMb CHOMb 
no siRNA ctrl siRNA 
NDUFAF1 
siRNA 
control  
siRNA 
 38 
 
Figure 20. Myoglobin mediates cell survival through reduction of nitrite to nitric oxide to S-nitrosate 
complex I and inhibit ROS production.  
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4.2 AIM 2 
As previously described, myoglobin is known for its expression in rapidly respiring cells, 
specifically cardiac and skeletal muscle cells where it is expressed in very high concentrations 
[16, 18]. However, myoglobin is now recognized for its expression in other cell types, including 
cancer tumors [22-24]. Myoglobin was first discovered by accidental staining in several human 
carcinomas in 2001. Since this initial discovery, myoglobin has been found it be expressed in 
several cancers of epithelial origin, including breast, ovary, colon and lung cancer [22].  
In 2010, Kristiansen et al. found that myoglobin expression is associated with better 
patient prognosis. As shown in the ten-year Kaplan-Meyer curve in Figure 21, patients with 
myoglobin positive tumors (Mb+) have significantly better survival than those with myoglobin 
negative tumors (Mb-) [22]. Notably, however, it is still unknown what myoglobin is doing in 
these tissues to improve patient outcomes. Therefore, the hypothesis for this aim is that 
myoglobin causes a reduction in cell proliferation in breast cancer cells through modulation of 
mitochondrial function and dynamics.  
 
Figure 21. Patients with myoglobin positive tumors (Mb+) have significantly better survival than patients 
with myoglobin negative (Mb-) tumors [22].  
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4.2.1 Stable transfection of human myoglobin in MDA-MB-231 cells  
To determine how myoglobin affects proliferation of breast cancer cells, the breast cancer cell 
line MDA-MB-231, which contains no endogenous myoglobin, was utilized. These cells were 
transfected to stably express human myoglobin (231Mb). A representative western blot in Figure 
22 shows control MDA-MB-231 cells (231) do not contain myoglobin and 231Mb cells were 
successfully transfected to stably express human myoglobin.  
 
Figure 22. 231 cells were successfully transfected to stably express human myoglobin (231Mb).   
 
To verify that stable expression of human myoglobin does not cause any significant 
changes in overall morphology of 231 cells, bright field images were taken with a 10X objective 
of both cell lines. These images revealed that myoglobin expression does not cause any obvious 
morphological changes (Figure 23).   
 
Figure 23. Stable transfection of myoglobin in 231 cells does not alter overall cell morphology. Bright field images 
show 231 control cells (left) and 231Mb cells (right) transfected to stably express human myoglobin.   
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4.2.2 Myoglobin expression decreases proliferation and migration of MDA-MB-231 cells  
To begin investigating the function of myoglobin in breast cancer cells, the proliferation of 231 
and 231Mb cells was first analyzed. As shown in Figure 24, 24-hour 3H thymidine incorporation 
showed that 231Mb cells have significantly lower proliferation compared to 231 control cells 
(p<0.01). Additionally, cell migration was analyzed by a 24-hour scratch assay. The percentage 
scratch closure was determined to quantify the migratory capability of the cells. 231Mb cells 
showed significantly less migration compared to 231 control cells (p<0.05). Representative 
images taken at 0 and 24 hours are shown in Figure 25 A with quantification in Figure 25 B. 
 
Figure 24.  231Mb cells proliferate significantly less than 231 control cells measured by 24-hour 3H thymidine 
incorporation. 231 proliferation rates are normalized to 1.00 and 231Mb rates represented as a percentage of 231. 
Data are presented as mean ± SEM. (* p<0.01). 
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Figure 25. Myoglobin expression significantly reduces cell migration. Cell migration was measured by a 24-hour 
scratch assay with the percent scratch closure calculated at the 24-hour time point. Representative images are shown 
in A and quantification shown in B. Data are presented as mean ± SEM. (# p<0.05).  
 
4.2.3 Myoglobin expression does not increase apoptosis  
Lower 3H thymidine incorporation could be due to either less proliferation or more apoptosis. To 
be sure the lower 3H thymidine incorporation observed in the 231Mb cells was due to less 
proliferation, apoptosis was measured by annexin V staining and flow cytometry analysis. As 
shown in Figure 26, 231 and 231Mb cells do not have significantly different annexin V positive 
cells (p=0.2).  
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Figure 26. Myoglobin expression does not increase apoptosis. Flow cytometry analysis of annexin V staining shows 
no significant difference between 231 and 231Mb cells. Data are presented as mean ± SEM. (p=0.2) 
 
4.2.4 Myoglobin expression in 231 cells is associated with mitochondrial fusion   
Because there is a significant difference in proliferation and migration of 231 and 231Mb cells 
and a significant amount of ATP is necessary to support these processes, myoglobin’s effect on 
mitochondria was investigated. First, the overall morphology of mitochondria in 231 and 231Mb 
cells was examined. Immunofluorescence staining of TOM20, a protein localized to the outer 
mitochondrial membrane, showed that 231 control cells have small, fragmented mitochondria 
(Figure 27A) while 231Mb cells have large networks of fused mitochondria (Figure 27B). 
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Mitochondria morphology was also analyzed by electron microscopy at 15,000X. 
Consistent with TOM20 staining, electron microscopy analysis showed 231 cells have 
fragmented mitochondria while 231Mb cells have fused mitochondria. Representative images are 
shown in Figure 28A. The extent of mitochondrial fusion was determined by calculating 
mitochondria interconnectivity, which can be quantified as area to perimeter ratio. This 
quantification showed 231Mb cells have significantly greater mitochondria interconnectivity 
compared to 231 control cells, shown in Figure 28B. 
 
Figure 27. 231Mb cells have significant mitochondrial fusion. TOM20 staining of the outer mitochondrial 
membrane of 231 (A) and 231Mb (B) cells shows 231 cells have small, fragmented mitochondria whereas 231Mb 
cells have fused mitochondria. 
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Figure 28. 231Mb cells show significantly greater mitochondria interconnectivity by electron microscopy. 
Representative electron microscopy images of mitochondria of 231 and 231Mb (A) cells imaged at 15,000X and 
ImageJ quantification (B) show 231 control cells have small, fragmented mitochondria while 231Mb cells have 
fused, elongated mitochondria. Mitochondria interconnectivity is presented as mean ± SEM. (# p<0.05). 
4.2.5 Mitochondrial fusion in 231Mb cells is due to upregulation of mfn1 & 2 and 
downregulation of drp1  
As previously described, mitochondria are very dynamic structures, constantly coming together 
through the process of fusion and breaking apart during fission. The mitofusin proteins (mfn 1 & 
2) are responsible for mediating fusion while dynamin related protein-1 (drp1) is responsible for 
mediating fission [8, 9]. 
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The expression of mitochondrial fission (drp1) and fusion (mfn1 &2) proteins was 
analyzed to determine whether altered expression of these proteins was responsible for the fusion 
observed in the 231Mb cells. As shown in Figure 29, western blot and densitometry analysis of 
these proteins revealed that 231Mb cells have significantly greater expression of the fusion 
proteins mfn1 and a strong trend for increased expression of mfn2. Furthermore, 231Mb cells 
have significantly lower expression of the fission protein drp1. This suggests myoglobin is 
driving mitochondrial fusion by increasing mfn1 expression and decreasing drp1 expression. 
 
 
Figure 29. Mfn 1 & 2 are upregulated and drp1 downregulated in 231Mb cells. Western blot and densitometry 
quantification shows 231Mb cells have significantly greater mfn1 expression (* p<0.01), a strong trend for increased 
mfn2 expression, and significantly lower expression of drp1 (# p<0.05) than 231 control cells. Protein expression is 
normalized to β-actin expression and represented as mean ± SEM.  
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4.2.6 Myoglobin expression is responsible for reduced proliferation in 231Mb cells 
Thus far, it has been shown that myoglobin expression is associated with a reduction in 
proliferation.  
 
Figure 30. Myoglobin expression is associated with mitochondrial fusion and reduced cell proliferation. 
 
To investigate whether myoglobin expression is responsible for causing decreased 
proliferation in 231Mb cells, myoglobin was knocked-down by siRNA transfection in 231 and 
231Mb cells and the proliferation analyzed over 24 hours by crystal violet staining. When 
transfected with non-targeted control siRNA, 231Mb cells proliferate significantly less than 
231Mb cells. Silencing myoglobin in 231 control cells had no effect on proliferation, which 
would be expected, as these cells do not contain any myoglobin. However, silencing myoglobin 
in 231Mb cells resulted in a significant increase in proliferation, with proliferation rates restored 
to the level of 231 control cells (Figure 31).  
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Figure 31. Silencing myoglobin by siRNA transfection in 231Mb cells restores proliferation. When 231 and 231Mb 
cells are transfected with control siRNA, 231Mb cells proliferate significantly less than 231 control cells (** 
p<0.001). When myoglobin is silenced, proliferation is restored in 231Mb cells (*** p<0.0001). Proliferation rates 
are normalized to 231 and represented as a percent of 231 control group. Data are presented as mean ± SEM.  
 
4.2.7 Mitochondrial fusion is responsible for reduced proliferation in 231Mb cells 
To determine whether mitochondrial fusion is also responsible for lower proliferation in 231Mb 
cells, the mitochondrial fusion proteins mfn1 and mfn2 were silenced by siRNA transfection in 
231 and 231Mb cells. Upon transfection of either mfn1 or mfn2 in 231 cells, proliferation 
increased slightly, as these cells do not have extensively fused mitochondria and thus silencing 
the fusion proteins would not have made a significant impact on the mitochondria. However, 
silencing either mfn1 or mfn2 in the 231Mb cells resulted in a significant increase in 
proliferation, restoring proliferation to that of 231 control levels (Figure 32). These findings 
suggest that in addition to myoglobin, mitochondrial fusion is also a driving force of the 
decreased proliferation.  
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Figure 32. Silencing mfn 1 & 2 by siRNA transfection restores proliferation of 231Mb cells. When 231 and 231Mb 
cells are transfected with control siRNA, 231Mb cells proliferate significantly less than 231 control cells (** 
p<0.001). When mfn 1 & 2 are silenced, proliferation is restored in 231Mb cells (*** p<0.0001). Proliferation rates 
are normalized to 231 and represented as a percent of 231 control group. Two-way ANOVA with a Bonferroni 
correction was used to determine significance. Data are presented as mean ± SEM. 
 
4.2.8 Myoglobin expression causes cell cycle arrest at the G1/S phase transition of the cell 
cycle    
The mitochondrial phenotype observed in 231 and 231Mb cells was an interesting finding, as 
mitochondrial dynamics regulate the cell cycle. As shown by Lippincott-Schwartz et al. in 2009 
and Yamano and Youle in 2011, proliferating cells as well as cells progressing from the G2 to M 
phase of the cell cycle have punctate, fragmented mitochondria whereas cells progressing from 
G1 to S phase have fused, elongated mitochondria (Figure 33) [48, 49]. Lippincott-Schwartz et 
al. further showed that mitochondria can become hyperfused at the G1/S phase transition, which 
causes cell cycle arrest.  
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Figure 33. Cells progressing from G2 to M phase of the cell cycle have fragmented mitochondria and cells 
progressing G1 to S phase have elongated, fused mitochondria [48, 49]. 
 
 This is particularly interesting, as the mitochondrial phenotypes of 231 and 231Mb cells 
is exactly that of proliferating cells and cells going through the G1/S phase transition, 
respectively. To determine whether the excessive mitochondrial fusion in 231Mb cells causes 
cell cycle arrest at the G1/S phase transition, the expression of cyclin E and p21 were analyzed. 
Cyclin E and p21 are proteins that regulate cell cycle progression specifically as cell progress 
from G1 to S phase. Cyclin E is necessary for cells to pass into S phase whereas p21 is causes 
growth arrest at this transition and is also a mediator of cellular senescence. 
 
 51 
Western blot analysis of cyclin E and p21 in 231 and 231Mb cells revealed that 231Mb 
cells have significantly lower cyclin E expression and significantly greater p21 expression than 
231 control cells (Figure 34). These results suggest that 231Mb cells are unable to pass from G1 
to S phase and thus experience cell cycle arrest at this transition. Therefore, as shown in the 
schematic in Figure 35, myoglobin expression causes mitochondrial hyperfusion to cause cell 
cycle arrest and reduce proliferation. 
 
Figure 34. 231Mb cells have significantly lower cyclin E expression and significantly greater p21 expression. 
Densitometry analysis of cyclin E and p21 expression levels show 231Mb cells have significantly lower cyclin E 
expression (A) and significantly higher p21 expression (B). Protein expression is normalized to β-actin or α-Tubulin 
expression and represented as mean ± SEM. (# p<0.05; * p<0.01) 
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Figure 35. Myoglobin expression is associated with mitochondrial fusion, which causes cell cycle arrest and reduces 
cell proliferation.  
4.2.9 Myoglobin-expressing tumors have lower end-tumor volume and weight than 
control tumors  
While all in vitro experiments showed that myoglobin expression and mitochondrial fusion drive 
a decrease in proliferation in breast cancer cells, it was unknown whether this mechanism was 
relevant in a model of cancer in vivo. To test this, 5 scid mice were injected in both mammary fat 
pads with 3 × 106 231 control cells or 231Mb cells. Tumors were allowed to grow until tumors of 
the control group reached a volume of 1.5cm3, when animals were sacrificed and final tumor 
volume and weight analyzed. Consistent with the in vitro proliferation results, the myoglobin-
expressing tumors showed a strong trend for lower tumor volume (Figure 36A) and weight 
(Figure 36B) compared to control tumors.  
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Figure 36. Myoglobin-expressing tumors show a strong trend for reduced end tumor volume and weight. N=5 mice 
per group. Data are presented as mean ± SEM.  
 
4.2.10 Myoglobin-expressing tumors have a fused mitochondrial phenotype 
Because the mitochondrial phenotype in 231 control and 231Mb cells were drastically different, 
to determine whether the same changes in the myoglobin cells also occur in vivo, the 
mitochondrial morphology of the tumors was also analyzed by electron microscopy. These 
results showed that myoglobin-expressing tumors have elongated, fused mitochondria while the 
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control tumors have punctate, fragmented mitochondria, shown in Figure 37A. The extent of 
mitochondrial fusion was quantified by area/perimeter ratio, with myoglobin-containing tumors 
having significantly greater interconnectivity (p<0.05) (Figure 37B).  
 
 
Figure 37. Myoglobin-expressing tumors have fused mitochondria. Electron microscopy analysis of tumor tissue 
show that myoglobin-expressing tumors have elongated, fused mitochondria whereas control tumors have punctate, 
fragmented mitochondria (A). Mitochondria interconnectivity was quantified by the ratio of area to perimeter, with 
myoglobin tumors having significantly greater mitochondrial interconnectivity. Data are expressed as mean ± SEM. 
(#p<0.05). 
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4.2.11  Myoglobin-expressing tumors show cell cycle arrest at the G1/S phase transition 
Since myoglobin-expressing tumors showed a trend for reduced proliferation and fused 
mitochondria, consistent with what was observed in 231Mb cells in vitro, it was hypothesized 
that the tumor cells may also be experiencing cell cycle arrest at the G1 to S phase transition. 
Thus, cyclin E and p21 expression levels were analyzed in the tumor tissue. Western blot 
analysis results showed that myoglobin-expressing tumors have significantly lower expression of 
cyclin E (p<0.05) and significantly greater p21 expression (p<0.05) compared to control tumors. 
Western blot images and densitometry quantification for cyclin E and p21 are shown in Figure 
38A and B, respectively. These findings suggest myoglobin-expressing tumors may be 
experiencing cell cycle arrest, consistent with the in vitro analysis of 231Mb cells.  
 
Figure 38. Myoglobin-expressing tumors have significantly lower cyclin E expression and significantly greater p21 
expression. Western blot analysis of cyclin E is shown in A and p21 in B. Protein expression is normalized to α-
Tubulin expression and represented as mean ± SEM. (# p<0.05) 
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4.2.12 231Mb cells and myoglobin-expressing tumors have decreased parkin expression  
Thus far, the results presented show that myoglobin expression is associated with mitochondrial 
hyperfusion, which causes cell cycle arrest and reduces cell proliferation (Figure 35). However, 
it is still unknown how myoglobin causes mitochondrial fusion.   
One protein of interest is parkin, which is an E3 ubuqitin ligase protein. Parkin is 
responsible for transferring ubiquitin to mitofusins on the outer mitochondrial membrane, 
thereby causing them to be degraded and preventing mitochondrial fusion, hence promoting 
mitochondrial fragmentation (Figure 39) [50, 51]. 
 
Figure 39. Parkin causes mitofusin ubiquitination, thereby inhibiting mitochondrial fusion. 
 
To determine whether this was the mechanism by which fusion occurs in myoglobin-
expressing cells and tumors, western blot analysis was done to assess parkin expression levels. 
Western blot analysis and densitometry quantification shown in Figure 40A of 231 and 231Mb 
cells showed that 231Mb cells have significantly lower expression of parkin compared to 231 
control cells. Similarly, myoglobin-expressing tumors also have significantly lower parkin 
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expression than control tumors (Figure 40B). Therefore, myoglobin expression reduces parkin 
expression, which inhibits mitofusin ubiquitination to cause mitochondrial hyperfusion (Figure 
41).  
 
 
Figure 40. 231Mb cells and myoglobin-expressing tumors have significantly lower parkin expression and control 
cells and tissue. Protein expression is normalized to β-actin expression and represented as mean ± SEM. (# p<0.05; 
* p<0.01). 
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Figure 41. Myoglobin could cause a reduction in parkin expression to inhibit mitofusin ubiquitination and drive 
mitochondrial fusion. 
 
4.2.13 Myoglobin expression reduces mitofusin ubiquitination  
It has been shown that myoglobin causes a reduction in parkin expression. To determine whether 
this reduction in parkin results in a reduction of mitofusin ubiquitination to drive mitochondrial 
fusion, mfn1 was immunoprecipitated in 231 and 231Mb cells and ubiquitination determined by 
western blot. These results show that 231Mb cells have significantly less ubiquitination of mfn1 
than 231 control cells (Figure 42) (p<0.05).  
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Figure 42. 231Mb cells have less mfn1 ubiquitination than 231 control cells. Western blot and densitometry 
analysis show mfn1 is ubiquitinated less in 231Mb cells than in 231 cells. Ubiquitin levels are normalized to mfn1 
expression in each cell type. Data are presented as mean ± SEM. (# p<0.05). 
 
As shown in the proposed pathway in Figure 43, the results presented here show that 
myoglobin expression causes a reduction in parkin expression, which reduces mfn1 
ubiquitination. With reduced mfn1 ubiquitination, mfn1 will not be degraded, thereby resulting 
in mitochondrial hyperfusion. As described, mitochondrial hyperfusion causes cell cycle arrest at 
the G1/S transition of the cell cycle, thereby causing a reduction in cell proliferation and tumor 
growth. 
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Figure 43. Myoglobin expression causes a reduction parkin expression to decrease mfn1 ubiquitination and drive 
mitochondrial fusion to cause cell cycle arrest and reduce cell proliferation. 
 
4.2.14 231Mb cells have cytosolic but not mitochondrial ROS   
One way in which parkin expression could be reduced is through its inactivation by oxidation. 
Notably, myoglobin is able to catalyze ROS production in the cytosol of the cell through its 
reaction with H2O2 [52]. 
Fe2+ + H2O2  Fe4+  Fe3+ + OH + OH- 
To determine whether myoglobin expression causes an altered intracellular oxidative 
state in 231Mb cells, mitochondrial and cytosolic ROS production was measured in 231 control 
and 231Mb cells. Mitochondrial-produced ROS was measured by the MitoSOX™ Red assay, 
which measures mitochondrial superoxide. There was no difference in superoxide produced 
between 231 control and 231Mb cells, as shown in Figure 44 (p=0.5).  
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Figure 44. Myoglobin expression does not change amount of mitochondrial-produced ROS. As measured by the 
MitoSOX™ Red assay, there is no significant difference in mitochondrially-produced ROS in 231 and 231Mb cells. 
(p=0.5) 
 
Cytosolic hydrogen peroxide generation was measured by the Amplex® Red assay. Cells 
were also treated with 0, 250, or 500nM mitoTEMPOL to scavenge mitochondrial ROS. Upon 
treatment of 231 cells with mitoTEMPOL, H2O2 production decreases, suggesting some of this 
ROS is originating from mitochondria. However, in 231Mb cells, treatment with mitoTEMPOL 
does not affect H2O2 production. These results are shown in Figure 45. 
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Figure 45. 231Mb cells do not produce mitochondrial ROS. As measured by the Amplex® Red assay and treating 
with mitoTEMPOLto scavenge mitochondrially-produced ROS, ROS production is not reduced in 231Mb cells. (** 
p<0.001, * p<0.01) 
 
4.2.15 Myoglobin expression causes parkin oxidation in 231Mb cells  
Because 231Mb cells produce a significant amount of cytosolic ROS, this ROS could oxidize 
parkin. Oxidized parkin is unable to mediate ubiquitination of mfns, thus resulting in excessive 
mitochondrial fusion Parkin oxidation was measured by a modified biotin switch assay in which 
parkin in pulled down by immunoprecipitation and oxidized residues labeled with biotin. Biotin 
levels are then normalized to the amount of parkin in the cell. As shown in Figure 46, these 
results revealed parkin oxidation is significantly greater in 231Mb cells. 
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Figure 46. Parkin oxidation is significantly increased in 231Mb cells. Biotin levels are normalized to 
parkin levels in the cell. Data are presented as mean ± SEM. (# p<0.05) 
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5.0  DISCUSSION 
Although myoglobin was first discovered over 100 years ago and its 3-dimensional structure 
resolved by X-ray crystallography over 50 years ago, new functions and locations of myoglobin 
are still being discovered today. As several groups have shown, myoglobin is expressed in 
tissues besides skeletal muscle including cancer tumors of non-muscle origin and has functions 
beyond oxygen storage and transport [22]. Specifically, myoglobin is able to scavenge or 
generate nitric oxide depending on oxygen tension in the cell [21]. As demonstrated in this 
thesis, these novel functions of myoglobin are important in mitochondrial regulation, particularly 
in ischemia/reperfusion injury and breast cancer.  
The ubiquitously expressed anion nitrite is known to be protective against 
ischemia/reperfusion injury [ref]. In 2013, Chouchani et al. demonstrated that this protection 
occurs through S-nitrosation of the ND3 subunit of complex I, causing inactivation of complex I, 
which inhibits ROS production during reperfusion [47]. Here, the mechanism by which nitrite is 
reduced to nitric oxide to mediate complex I protection to promote cell survival was investigated.  
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Utilizing CHOR cells not expressing myoglobin and stably transfecting them to generate 
myoglobin-expressing CHOMb cells, it was shown by simulating ischemia/reperfusion in vitro 
that myoglobin is necessary for nitrite to mediate protection after ischemia/reperfusion (Figure 
16). Moreover, by knocking down complex I of the electron transport chain in CHOR and 
CHOMb cells, it was shown that this protection occurs through complex I (Figure 19). It was 
also verified that the nitrite-mediated complex I protection occurs though S-nitrosation (Figure 
17).  
With this insight into the mechanism by which myoglobin and nitrite mediate protection 
in ischemia/reperfusion injury, nitrite treatment can be better targeted to cell types expressing 
myoglobin and nitrite dosing can be better tailored to meet a specific tissue’s myoglobin content. 
Ischemia/reperfusion occurs in several pathological contexts including myocardial infarction, 
stroke, and organ transplantation. With the understanding of how nitrite reacts with myoglobin to 
reduce cell death and tissue damage, nitrite could be used to treat ischemia/reperfusion of other 
tissues. For example, during organ transplantation, the transplanted organ undergoes relatively a 
relatively long period of ischemia before reperfusion. However, it has been recognized that much 
of the tissue damage occurs during reperfusion injury. This injury to the tissue can result in 
delayed graft function as well as acute or chronic rejection [52]. With the emerging evidence that 
myoglobin is expressed in several tissues beyond skeletal muscle, some transplanted tissues may 
contain myoglobin, which would then allow for nitrite treatment to be utilized to reduce tissue 
damage during the reperfusion period after transplantation. In tissues that do not contain 
myoglobin, protein therapy may be utilized to force expression of myoglobin in order to allow 
nitrite treatment to be used to prevent tissue damage. Protein therapy, an emerging technology 
that is currently being investigated in several clinical trials, delivers a therapeutic level of a 
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protein to cells. There are several ways in which proteins can be delivered to the cell including 
PEGylation, nanoparticles, hyperglycosylation, and liposomes [53]. By forcing expression of 
myoglobin and treating with nitrite, during the ischemic period would cause respiration to be 
inhibited, thereby reducing cell death at the onset of reperfusion and ultimately preserving organ 
function. 
While myoglobin has been shown to be protective by reducing cell death in 
ischemia/reperfusion, it has also emerged as a protective mechanism in cancer [22-24]. 
Investigation into myoglobin expression in breast cancer by Kristiansen and colleagues revealed 
that myoglobin expression is associated with better patient outcomes [22]. However, the role 
myoglobin plays in these tissues is not yet understood. By developing breast cancer cells that 
stably express human myoglobin, aim 2 of this thesis investigated how myoglobin affects cell 
proliferation and mitochondrial dynamics. Stably transfecting 231 breast cancer cells with human 
myoglobin (231Mb) revealed that myoglobin significantly reduces the proliferation of these cells 
(Figure 24). The effect of myoglobin expression on mitochondria was investigated by first 
examining overall mitochondria morphology. These results revealed that myoglobin-expressing 
cells have significant mitochondrial fusion while 231 control cells have very fragmented, 
punctate mitochondria (Figure 27 & Figure 28).  
Interestingly, it has been shown by several groups that mitochondrial dynamics regulate 
the cell cycle. Specifically, proliferating cells have fragmented mitochondria whereas cell 
progressing from the G1 to S phase of the cell cycle have elongated, fused mitochondria. 
Mitochondrial hyperfusion can also occur at the G1/S transition, causing cell cycle arrest [48, 
49]. Therefore, 231 cells have the mitochondrial phenotype of proliferating cells and 231Mb 
cells have a hyperfused phenotype and may be experiencing cell cycle arrest. Analysis of 
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expression of cyclin E and p21 expression, mediators of cell cycle progression at the G1/S 
transition, revealed that 231Mb cells have lower cyclin E and greater p21 expression than 231 
control cells (Figure 34). Because cyclin E is required for cells to enter S phase of the cell cycle 
and p21 inhibits progression into S phase, these results suggest 231Mb cells experience cell 
cycle arrest at the G1/S phase transition.  
Investigation into how myoglobin causes mitochondrial fusion, expression of the E3 
ubiquitin ligase protein parkin was analyzed. Parkin, which facilitates ubiquitination of mitofusin 
proteins, was found to be expressed at lower levels in 231Mb cells than 231 control cells (Figure 
40). Thus, in 231Mb cells, mitofusins are ubiquitinated to a lesser extent, thereby causing 
mitochondrial hyperfusion to reduce cell proliferation.  
Myoglobin expression in cancer is particularly interesting because its expression in these 
cells, which typically grow and divide extremely rapidly, causes a reduction in cell proliferation, 
thereby serving as a protective mechanism. This insight into how myoglobin may be a mediator 
of cell proliferation could be employed in several applications. For example, protein therapy 
could be utilized to reduce proliferation in cells that do not typically express myoglobin or have 
low myoglobin expression. This could be particularly interesting in smooth muscle cells, as rapid 
proliferation of smooth muscle cells becomes important in the progression of atherosclerosis. 
Although these cells have been shown to express myoglobin, it is only expressed in low levels 
[21]. Therefore, protein therapy could be used to force myoglobin expression and potentially 
inhibit smooth muscle cell proliferation to slow disease progression.  
It would also be interesting to investigate whether myoglobin is expressed in various 
stages of development. Through development, cells go through stages in which they proliferate 
very rapidly and many eventually stop regenerating completely. For proper development, 
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proliferation of each cell type needs to be coordinated and very tightly regulated. It would be 
interesting to investigate whether myoglobin expression is one way in which these cells 
transform from rapidly proliferating to terminally differentiated cells.  
Myoglobin expression in cancer also poses a novel therapeutic target for treatment. In 
2008, Wittenberg suggested non-toxic concentrations of carbon monoxide could be used to target 
myoglobin in these tumors [22]. Myoglobin expression could also be used to classify breast 
cancer cases in order to provide better treatment options and better understand the progression of 
the disease for individual patients. In breast cancer patients with myoglobin negative tumors, 
myoglobin could be used as protein therapy to reduce proliferation and spread of the cancer. 
Although this is not a treatment for cancer, it could aid in significantly reduce tumor growth, 
which would allow the cancer to be treated more effectively.  
In summary, myoglobin and mitochondria have long been known to be critical for normal 
cell function; however, they have only recently been recognized to interact. Here, it is shown that 
myoglobin is necessary to reduce nitrite to nitric oxide for protection against cell death after 
ischemia/reperfusion injury, thereby promoting cell survival. Additionally, it is shown that 
myoglobin functions as a protective mechanism in breast cancer, modulating mitochondrial 
dynamics to reduce cell proliferation and tumor growth. It is clear that myoglobin has a wide 
variety of functions and although it was once thought of only as an oxygen storage protein, it 
may play a role in more diseases than what is currently understood.  
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6.0  FUTURE DIRECTIONS 
This project showed that nitrite is reduced to nitric oxide by myoglobin in hypoxia, which S-
nitrosates complex I to reduce cell death in reperfusion. However, the method used verified this 
protection occurs through complex I by knocking down the entire complex, which may cause 
additional complications within the cell that may have other effects not obvious in this 
experiment. A better, more focused approach would be to mutate the cysteine 39 on the ND3 
subunit of complex I, which is the residue Chouchani et al. found to be modified after nitrite 
treatment in ischemia/reperfusion [47]. In this case, other effects of knocking down complex I 
would be eliminated and it would be further validated that the protection occurs by S-nitrosation 
of this residue. Unfortunately, however, this method cannot be utilized. The complexes of the 
electron transport chain are encoded by mitochondrial DNA. Although much research has been 
invested into studying the mitochondrial genome, to date a method to modify the DNA has not 
yet been developed [54].  
 An alternative would be to measure the activity of all complexes of the electron transport 
chain in CHOR and CHOMb cells with and without nitrite treatment after ischemia/reperfusion 
simulation. With nitrite treatment, the activity of complex I in CHOMb cells should be 
significantly reduced, since nitrite S-nitrosates the ND3 subunit to inhibit complex I and mediate 
protection. In the CHOR cells, complex I activity should not be inhibited significantly, as 
electrons will continue to enter the chain at this complex, which will leak out, eventually 
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resulting in ROS production (Figure 11). Additionally, it would be useful to measure ROS 
production in the CHOR and CHOMb cells after ischemia/reperfusion to determine how much 
nitrite reduces ROS production in CHOMb cells. 
 While the results presented in this thesis suggest myoglobin may significantly reduce 
breast cancer cell proliferation, further research is warranted. It is important to study the effect of 
myoglobin expression on other cancer cell types. The MDA-MB-231 cell line is triple negative 
cell line, meaning it does not have receptors for estrogen (ER), progesterone (PR), or HER-
2/neu. However, only between 10 and 17% of breast cancers are triple negative while 65% are 
PR positive and 75% ER positive [55]. Therefore, for this research to be most clinically relevant, 
it is important to understand how myoglobin’s effects differ based on hormone receptor status. 
Specifically, the MCF-7 cell line, which is ER and PR positive, could be used to study the effect 
of positive hormone receptor status. Further, because some patients have highly metastatic breast 
cancer while others do not experience metastasis, it would also be beneficial to study cell lines 
with different metastatic ability. The cell line MDA-MB-468 could be used to determine whether 
myoglobin expression has different effects depending on the metastatic ability of the cells. The 
MDA-MB-468 cell line is also triple negative; therefore by comparing these results to the 
proliferation results of MDA-MB-231 cells, myoglobin’s effect on cells of different metastatic 
ability could be investigated independent of hormone receptor status. Another important avenue 
to explore is the effect of myoglobin expression on premalignant human breast epithelial cells. 
To investigate whether myoglobin has the same antiproliferative effect on cells before they are 
considered cancerous, MCF-10A cells, which are normal breast epithelial cells, could be 
transfected with myoglobin. This would provide insight into when myoglobin may begin to be 
expressed in breast cancer, before or after the cell becomes tumorigenic.   
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The results presented in this thesis suggest myoglobin may act as a tumor suppressor by 
reducing breast cancer cell proliferation. It is important to test whether this phenomenon occurs 
in other cell types, including other types of cancer. Preliminary results from Galluzzo et al. in 
2009 suggest myoglobin expression in lung cancer cells also reduces proliferation and delays 
tumor engraftment in-vivo [56]. Therefore, the effect of forced myoglobin expression should be 
investigated in several cancer cell types including lung, colon, and ovary, because it has been 
reported that these tumor types show myoglobin expression in vivo. It is also important to 
investigate whether myoglobin’s ability to reduce cell proliferation is translatable to other non-
cancerous cell types. Preliminary results from our lab suggest myoglobin expression in the CHO 
cell line does not have the same effect on proliferation as in the MDA-MB-231 cells. Therefore, 
this phenomenon of myoglobin reducing cell proliferation may be unique to cancer cells, which 
could provide significant advancements in the treatment of cancer and understanding of its 
progression.  
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Additionally, although the preliminary results presented here suggest myoglobin reduces 
tumor growth in vivo, it is necessary to perform further animal experiments. For example, other 
injection methods could be utilized. In this project, 3 × 106 cells were injected into the mammary 
fat pad of the mice, which can result in significant cell death and few cells are actually implanted 
and contribute to tumor formation. Alternatively, a subcutaneous injection method could be used.  
Several other aspects of tumor growth should also be investigated including metastatic spread to 
foreign tissues and angiogenesis at the site of the tumor. Because it was found that 231Mb cells 
migrate significantly less than 231 control cells, metastasis would be interesting to investigate, as 
breast cancer is known to metastasize to several tissues, specifically the lungs, brain, bone, and 
liver. By injecting mice with breast cancer cells through tail vein injection, metastasis to the 
lungs can be studied.  
 The recent discovery of myoglobin in smooth muscle cells poses additional therapeutic 
uses for myoglobin. In atherosclerosis, and restenosis after stent placement, rapid proliferation of 
vascular smooth muscle cells contributes to progression of these disorders. Although these cells 
contain low levels of endogenous myoglobin, if myoglobin’s ability to reduce cell proliferation is 
translatable to smooth muscle cells, forcing myoglobin expression in these cells may be a means 
by which the progression of these disorders could be slowed. Moreover, it would be 
advantageous to examine whether the level of myoglobin expression changes as restenosis and 
atherosclerosis progress. This would provide insight into whether there is a molecular switch 
within the cells, causing them to proliferate excessively, and whether myoglobin contributes to 
this change in phenotype.  
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7.0  CONCLUSIONS 
This research confirms that myoglobin has several functions in addition to oxygen storage and 
delivery in skeletal muscle. Myoglobin was found to be essential for nitrite-mediated protection 
in ischemia/reperfusion injury through post-translational modification of complex I, which 
promotes cell survival and mitigates tissue damage. Moreover, myoglobin was shown to function 
as a protective mechanism to reduce cell proliferation in breast cancer both in vitro and in vivo 
through modulation of mitochondrial dynamics and function. This may contribute to improving 
patient prognosis in those patients with myoglobin-expressing tumors.  
 With these insights into how myoglobin modulates mitochondria, better understanding of 
disease progression can be established, which will allow for development of improved treatment 
methods. Moreover, with further research, the expression profile of myoglobin will continue to 
be clarified, which may allow for nitrite-based therapies to be utilized in additional applications 
such as organ transplantation.  In conclusion, myoglobin is a protein with several functions that 
are still being elucidated today and has the potential to be employed in treatment of disease and 
used to better understand disease progression.  
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